Yusra Murad


Yusra is a reporter at Morning Consult covering health care.

Morning Consult Health: Week in Review & What’s Ahead

By Yusra Murad   Week in Review Opioid epidemic The federal government, led by the National Institutes of Health and the Substance Abuse and Mental Health Services Administration, will award $350 million in grants over three years to research sites in Kentucky, Massachusetts, New York and Ohio focused on reducing opioid overdose deaths by as much […]

Morning Consult Health: Gene Therapy Cures 10 Newborns With Rare Genetic Disorder, Per Research Report

By Yusra Murad Top Stories Gene therapy cured 10 newborn babies afflicted with severe combined immunodeficiency disease, or “bubble boy disease,” a rare genetic disorder in which infants’ immune systems are dysfunctional, according to a report published in the New England Journal of Medicine. The treatment, developed by St. Jude Children’s Research Hospital and UCSF Benioff […]

Morning Consult Health: Johnson & Johnson’s Q1 Net Income Drops 14% but Prescription Sales Help Bolster Earnings

By Yusra Murad Top Stories Johnson & Johnson reported net income of $3.75 billion in its first-quarter earnings report, down 14 percent year-over-year, with sales rising from $20.01 billion to $20.02 billion. Although thousands of lawsuits alleging the company’s talc-based products caused consumers’ cancer have led to significant legal expenses, prescription drug sales have bolstered earnings, […]

Morning Consult Health: Catalent Reportedly Buying Paragon Bioservices in $1.2 Billion Deal to Expand Gene-Therapy Work

By Yusra Murad Top Stories Catalent Inc. will purchase drugmaker Paragon Bioservices Inc. in a $1.2 billion all-cash deal in an effort to build its gene-therapy manufacturing capabilities, according to people familiar with the deal, which is set to be announced this morning. The sources said Paragon, which provides supplies for pharmaceutical companies in the promising […]